Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality
This study has been completed.
Study NCT00065156   Information provided by Celgene Corporation
First Received: July 17, 2003   Last Updated: May 5, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Chromosome Aberrations
Congenital Abnormalities
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
CC-5013
Additional drug interventions recognized in this trial
Lenalidomide
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services